The randomised Complete versus Lesion-only PRimary percutaneous coronary Intervention Trial: Cardiovascular Magnetic Resonance imaging substudy (CvLPRIT-CMR)

Gerry P McCann,1,2* Jamal N Khan,1,2 John P Greenwood,3 Sheraz A Nazir,1 Miles Dalby,4 Nick Curzen,5 Simon Hetherington,6 Damian J Kelly,7 Daniel J Blackman,3 Arne Ring,8,9 Charles Peebles,5 Joyce Wong,4 Thiagarajah Sasikaran,10,11 Marcus Flather,12,13 Howard Swanton14 and Anthony H Gershlick1,2

1Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK
2NIHR Leicester Cardiovascular Biomedical Research Unit, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK
3Multidisciplinary Cardiovascular Research Centre and The Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
4Department of Cardiology, Royal Brompton and Harefield Foundation Trust, Harefield Hospital, Middlesex, UK
5Department of Cardiology, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK
6Department of Cardiology, Kettering General Hospital, Kettering, UK
7Department of Cardiology, Royal Derby Hospital, Derby, UK
8Leicester Clinical Trials Unit, University of Leicester, Leicester, UK
9Department of Mathematical Statistics and Actuarial Science, University of the Free State, Bloemfontein, South Africa
10Clinical Trials and Evaluation Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK
11Imperial Clinical Trials Unit, Imperial College London, London, UK
12Clinical Trials Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK
13Norwich Medical School, University of East Anglia, Norwich, UK
14Department of Cardiology, The Heart Hospital, University College London Hospitals, London, UK

*Corresponding author
Declared competing interests of authors: Dr McCann reports grants from Institut de Recherches Internationales Servier and Menarini International, outside the submitted work. Dr Curzen reports grants and personal fees from St Jude Medical and Haemonetics, grants from Medtronic, personal fees from Abbott Vascular and Heartflow, and non-financial support from Volcano Corporation, outside the submitted work. Dr Dalby reports providing consultancy services for Medtronic, Boston, AstraZeneca, Daichii Sankyo–Eli Lilly alliance and Sanofi and receiving grants from Abbott Vascular and Daichii Sankyo–Eli Lilly alliance, outside the submitted work. Professor Ring has received conference travel expenses from Boehringer Ingelheim, personal consultancy fees from Roche and research funding from Novartis outside the submitted work. Professor Flather reports serving on advisory and speaker panels for AstraZeneca and Menarini International outside the current work.

Published January 2016
DOI: 10.3310/eme03010

Plain English summary

CvLPRIT-CMR study
Efficacy and Mechanism Evaluation 2016; Vol. 3: No. 1
DOI: 10.3310/eme03010

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Specialist heart doctors increasingly treat patients who suffer large heart attacks as a matter of urgency with a procedure performed under local anaesthetic. The blocked blood vessel (artery) that causes the heart attack is opened by inserting a small metal scaffold (stent) at the blockage to hold the artery open. Up to 50% of patients treated in this way also have other narrowed, but not totally blocked, heart arteries. Two recent studies in patients with heart attacks and multiple narrowed arteries have suggested that treating all of the narrowed arteries may be better than just treating the blocked artery. However, there is concern that the longer procedure, and putting in more stents, may cause more damage to the heart. We studied 203 patients having a heart attack who were randomly assigned to have only the blocked artery (105 patients) or all the narrowings treated (98 patients) in seven hospitals in England. We assessed the amount of heart muscle damage that occurred using magnetic resonance imaging. Patients were more likely to have more than one area of heart muscle damage if all of their heart arteries were treated than if only the blocked artery was treated (22% vs. 11% of patients). However, the percentage of the heart that was damaged was not increased (12.6% vs. 13.5%) and the heart function 3 days and 9 months after treatment was similar with both treatments. The results of this study provide reassurance that specialists treating patients with a heart attack can open more than one narrowed artery without increasing the total amount of heart damage.
Efficacy and Mechanism Evaluation

ISSN 2050-4365 (Print)
ISSN 2050-4373 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nhredit@southampton.ac.uk

The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Efficacy and Mechanism Evaluation journal

Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme was set up in 2008 as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is broadly aimed at supporting ‘science driven’ studies with an expectation of substantial health gain and aims to support excellent clinical science with an ultimate view to improving health or patient care.

Its remit includes evaluations of new treatments, including therapeutics (small molecule and biologic), psychological interventions, public health, diagnostics and medical devices. Treatments or interventions intended to prevent disease are also included.

The EME programme supports laboratory based or similar studies that are embedded within the main study if relevant to the remit of the EME programme. Studies that use validated surrogate markers as indicators of health outcome are also considered.

For more information about the EME programme please visit the website: http://www.nets.nihr.ac.uk/programmes/eme

This report

The research reported in this issue of the journal was funded by the EME programme as project number 10/27/01. The contractual start date was in April 2011. The final report began editorial review in January 2015 and was accepted for publication in July 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by McCann et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).


Efficacy and Mechanism Evaluation Editor-in-Chief

Professor Raj Thakker  May Professor of Medicine, Nuffield Department of Medicine, University of Oxford, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk